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We report armA in an Escherichia coli pig isolate from
Spain. The resistance gene was borne by self-transferable
IncN plasmid pMUR050. Molecular analysis of the plasmid
and of the armA locus confirmed the spread of this resist-
ance determinant. 
A
minoglycosides are used to treat a broad range of life-
threatening infections in humans and animals (1,2).
Thus, surveillance of resistance to these antimicrobial
agents and study of the corresponding mechanisms in path-
ogenic bacteria remain ongoing challenges in microbial
research (3). Since 1996, the Spanish Veterinary
Antimicrobial Resistance Surveillance Network has moni-
tored antimicrobial resistance in both healthy and ill ani-
mals, with the aim of assessing the state of veterinary
antimicrobial resistance in Spain (4–6). Escherichia coli is
used as a model bacterium for the analysis of isolates from
sick animals. Veterinary diagnostic laboratories from offi-
cial and private sectors provide the isolates, following a
classic passive monitoring system with a centralized ana-
lytic approach. To avoid bias, a single isolate per farm per
year (or animal in the case of pets) is studied. The identity
of the farm (or owner) is kept confidential to facilitate par-
ticipation. In addition, isolates are included only if their
antimicrobial susceptibility has not been determined
before being sent to the network. Although formal sam-
pling is not performed, involvement of several laboratories
throughout the country elicits an accurate estimate of
antimicrobial susceptibility in Spain (4–6). From 1996 to
2003, the number of isolates tested was >2,300 for E. coli
and 700 for Staphylococcus aureus. 
The Study
E. coli MUR050 from the feces of a diarrheic pig was
isolated in 2002. Routine antimicrobial susceptibility test-
ing showed unusual resistance to amikacin. The isolate
was also resistant to other aminoglycosides (streptomycin,
gentamicin, and neomycin, but not apramycin), as well as
to members of other classes (sulfonamides, trimethoprim,
quinolones). Because of this unusual phenotype, the stan-
dard identification procedure (Gram staining, oxidase,
indol, methyl red, citrate, and Vogues-Proskauer) (6) was
confirmed by partial sequencing of the ribosomal 16S
rRNA gene (data not shown) (7). Additional study of
antimicrobial susceptibility by Etest (AB Biodisk, Solna,
Sweden) indicated that the strain was also highly resistant
to the 4,6-disubstituted deoxystreptamines netilmicin and
tobramycin (Table). We initiated an investigation to find
the molecular determinants of this pattern. Plasmid DNA
purified from MUR050 (Qiagen, Inc., Chatworth,
California, USA) was used to transform E. coli INVαF′
(Invitrogen, Paisley, United Kingdom) (8) to yield strain
INVαF′ (pMUR050), which was highly resistant to amino-
glycosides and sulfonamides. Resistance to aminoglyco-
sides and the sulfonamides could be transferred from
MUR050 to other E. coli by conjugation at a frequency of
≈1 × 10-4 per donor colony-forming unit (9). 
Search for antimicrobial resistance determinants by
polymerase chain reaction (PCR) using plasmid
pMUR050 DNA as template indicated the presence of
genes  sul1 for resistance to sulfonamides, ant3′′9 for
resistance to streptomycin-spectinomycin, and aph3′-I for
resistance to kanamycin and neomycin. Plasmid
pMUR050 DNA was digested with PstI and ligated with
pUC18 DNA; the ligation mixture was used to transform
INVαF′ cells that were plated on agar containing ampi-
cillin (50 µg/mL) and tobramycin (10 µg/mL). The result-
ing colonies harbored plasmid p18MUR050 with an insert
of ≈9 kb, which when sequenced showed armA, the struc-
tural gene for a 16S rRNAmethylase (10). To confirm that
armA was responsible for aminoglycoside resistance in
this strain, 2 oligonucleotides, armF (5′-GGTGC-
GAAAACAGTCGTAGT-3′) and armR (5′-TCCT-
CAAAATATCCTCTATGT-3′), were used to amplify
armA, which was purified, ligated into pUC18, and trans-
formed into E. coli INVαF′ with selection on ampicillin
and tobramycin. Transformant INVαF′ (parmA) was high-
ly resistant to 4,6-disubstituted deoxystreptamines (Table),
which demonstrated that armA was responsible for high-
level aminoglycoside resistance in MUR050. 
Until now, the armA gene has been found only on con-
jugative plasmids of the IncL/M incompatibility group and
associated with the blaCTX-M3 gene coding for a broad-
spectrum β-lactamase (11). Plasmid pMUR050, however,
did not confer resistance to the cephalosporins and did not
belong to the IncL/M family, as tested by PCR (data not
shown), which indicated that armA was carried by a differ-
ent replicon. Plasmid pMUR050 DNA was digested with
Sau3A, and the resulting fragments were ligated with plas-
mid pBluescript KS+ DNA (Stratagene, La Jolla, CA,
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INVαF′ and plated on agar containing ampicillin (50
µg/mL). The inserts of plasmids from 96 random clones
were sequenced with standard oligonucleotides with an
ABI Prism DNA Sequencer apparatus (Perkin-Elmer,
Foster City, CA, USA). Approximately half of the
sequence had a high degree of identity (80%–100%) with
genes of conjugative plasmid R46, which belongs to the
IncN incompatibility group (12). Among them, sequences
involved in plasmid replication and mobilization, such as
repA and oriT, were identified (data not shown), which
confirmed that armA was carried by an R46-like replicon.
This finding suggests that armA could be part of a mobile
genetic element that has translocated between plasmids of
diverse evolutionary origins. Upstream from armA an open
reading frame (ORF) has 69% identity with that of a trans-
posase from Listonella anguillarum (GenBank accession
no. AAO92373); this ORF and armA are flanked by 16-bp
directly repeated sequences with a single mismatch (5′-
aggtttccactacagt-3′) (GenBank accession no. AY522431).
However, since aminoglycosides are rarely used in porcine
production in Spain (13), and no veterinary drugs contain-
ing amikacin are registered, the sul1 and armA genes were
conceivably co-selected by the use of sulfonamides. These
antimicrobial agents are not among the 4 antimicrobial
agents authorized in Europe for growth promotion (14) but
are used orally to treat bacterial infections such as group E
streptococcal pneumonia or atrophic rhinitis and diarrhea
(2). 
Conclusions
These data support the notion that armA is disseminat-
ed both by conjugation and transposition, which makes
further spread of armA likely. The complete sequence of
plasmid pMUR050 is being determined and should help in
elucidating the genetic basis for dissemination of armA. 
The origin of the armA gene is still unknown.
Aminoglycoside-producing environmental bacteria pos-
sess 16S rRNA methylases to protect themselves from the
antimicrobial agent that they produce (15). In addition to
ArmA (11), 2 other 16S rRNA methylases have been
reported recently in human pathogens from Japan: RmtA
in Pseudomonas aeruginosa (16) and RmtB in Serratia
marcescens (17). One could speculate that actinomycetes
have transferred the methylase genes to pathogenic bacte-
ria in the environment that further spread on diverse repli-
cons in various hosts. However, the degree of identity of
armA with the structural genes for the 16S rRNA methy-
lases in actinomycetes is <30%, which is not compatible
with a recent transfer event. Alternatively, armA could
have originated from a yet unknown aminoglycoside-pro-
ducing actinomycetes (10). 
In 2003, armA was identified as a new determinant that
conferred high-level resistance to aminoglycosides in a
French clinical isolate of Klebsiella pneumoniae (10) and
was subsequently detected in human isolates of
Enterobacteriaceae from various countries in Europe (11).
The finding of armA in animal isolates shows that veteri-
nary monitoring networks should include last-resort
antimicrobial agents of high therapeutic value for humans,
which could help in detecting early subtle shifts in antimi-
crobial resistance. In fact, armA was detected in an animal
bacterium because amikacin was included in the standard
antimicrobial panel in the Spanish Veterinary
Antimicrobial Resistance Surveillance Network. Our find-
ing of armA in a bacterium of animal origin highlights the
importance of coordinated surveillance of human and ani-
mal isolates (18–20). 
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